Artificial intelligence–powered imaging-based diagnostic tools for ageing and longevity

Abstract

<p>When we talk about the broad research covering the ageing and longevity field, it can be initially split into two parts. First is therapeutics, which is the development of drugs or the repackaging of existing drugs for the purpose of tackling the ageing disease process. Recent examples of this include the use of metformin in the Targeting Aging with Metformin trial, in which investigators are looking to see if the drug has an impact on lifespan extension. The trial plans to include 3000 non-diabetic subjects, aged 70–80 years and burdened with at least one chronic disease, in at least 14 health centres across the United States to evaluate the effects of metformin on its primary endpoint, which are composites of the incidence of age-related conditions such as myocardial infarction, congestive heart failure, stroke, cancer, dementia, and death. The second focus is on the field of diagnostics. For the remaining part of this chapter, we will focus on the diagnostics aspects of ageing and longevity with particular emphasis on the use of machine learning and artificial intelligence.<br></p>